Tariq Sethi
Directeur Technique/Scientifique/R&D chez ONCIMMUNE HOLDINGS PLC
Profil
Tariq Sethi is the founder of Galecto Biotech ApS and Galecto, Inc. both founded in 2011.
He is currently the Chief Scientific Officer at Oncimmune Holdings Plc since 2019.
Dr. Sethi's former positions include being a Professor at The University of Edinburgh, and Head of Respiratory Medicine at King's College London and King's Health Partners Ltd.
Postes actifs de Tariq Sethi
| Sociétés | Poste | Début |
|---|---|---|
| ONCIMMUNE HOLDINGS PLC | Directeur Technique/Scientifique/R&D | 01/10/2019 |
Anciens postes connus de Tariq Sethi
| Sociétés | Poste | Fin |
|---|---|---|
| GALECTO, INC. | Fondateur | - |
| The University of Edinburgh | Corporate Officer/Principal | - |
King's Health Partners Ltd.
 King's Health Partners Ltd. Miscellaneous Commercial ServicesCommercial Services King's Health Partners Ltd. operates as an academic health sciences center. The company was founded in 2010 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
| King's College London | Corporate Officer/Principal | - |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| ONCIMMUNE HOLDINGS PLC | Health Technology |
| GALECTO, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Galecto Biotech ApS
Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
King's Health Partners Ltd.
King's Health Partners Ltd. Miscellaneous Commercial ServicesCommercial Services King's Health Partners Ltd. operates as an academic health sciences center. The company was founded in 2010 and is headquartered in London, the United Kingdom. | Commercial Services |
